Healthcare
Cybin Inc. Common Stock(HELP)
Live Price
Offline$4.67
+1.97% today
1Y Change
-42.19%
Window
Jun 30, 2025 โ Jun 23, 2026
- Market Cap
- $130.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +84.4%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 30, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cybin Inc. Common Stock (HELP) is a Healthcare stock with a market cap of $130.00M and listed on NASDAQ. The stock last traded around $4.67 and down 42.2% across the available one-year price window (Jun 30, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +84.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +84.4%, free cash flow -48.3% with operating margin 0.0% and ROIC -50.7%. Stock Foundry combines HELP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
Q1 2026 was reported on Feb 13, 2026 with an EPS surprise of -38.8%.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +84.4%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.7% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
Q1 2026 Feb 13, 2026 | -38.8% | +11.0% | +10.5% | -23.0% |
Q1 2026 Feb 3, 2026 | +0.3% | -4.2% | -3.5% | +28.5% |
Q1 2026 Jan 22, 2026 | +1.0% | -2.2% | -12.2% | -11.7% |
Benchmark Edge
HELP vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
HELP trails SPY
HELP is 60.92 pts behind over the shared 1Y window.
HELP had 47.87 pts deeper max drawdown than SPY.
HELP beat SPY in 0 of 2 calendar years shown and trailed in 2.
HELP
-42.19%
Normalized return
SPY
+18.73%
S&P 500
Excess Return
-60.92 pts
Relative to SPY
HELP Max Drawdown
-57.00%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for HELP and SPY.
| Year | HELP | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | -41.43% | +6.71% | -48.13 pts | SPY |
| 2025 | +2.15% | +11.19% | -9.05 pts | SPY |
Company Overview
Cybin Inc. Common Stock
NASDAQ Global Market
Clinical-stage biopharmaceutical company developing psychedelic-based therapeutics including CYB003 (deuterated psilocybin analog) for major depressive disorder and CYB004 (deuterated DMT) for generalized anxiety disorder
- Leadership
- Michael F. Cola
- IPO Date
- Sep 13, 2019
- Employees
- 50
- Street Address
- 100 King Street West
- Mailing
- Toronto, ON, M5X 1C9
- Region
- Toronto, ON, CA
- Reporting Currency
- USD
- Investor Line
- 908 764 8385
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.5
- Price/Sales
- โ
- Price/Book
- 0.8
Growth
- Revenue
- 0.0%
- EPS
- +84.4%
- Free Cash Flow
- -48.3%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -61.5%
- ROIC
- -50.7%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 13.78
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.